A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice

Sponsor
Novo Nordisk A/S
Study ID
NCT05473286
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oral Semaglutide — DRUG
    Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Study Details

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 34-44 weeks. Participants will be asked to complete questionnaires about how they take their Rybelsus® tablets. Participants will complete the questionnaires during their normally scheduled visit with the study doctor.

Key Dates

Start date
Sep 30, 2022
Status verified
Sep 2022
Primary completion
May 16, 2024
Completion
May 16, 2024

Study Design

Enrollment
0 participants (actual)

Arms

  • Arm: Patients with type 2 diabetes
    Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.

Primary Outcome Measure

Change in Glycated haemoglobin (HbA1c ) [ Time Frame: From baseline (week 0) to End of Study visit (V3) (week 34-44) ]

Related Studies